Researchers at Uppsala University in Sweden earlier found that nitric oxide is the only substance shown so far to have a direct effect on SARS-CoV-2,” says Åke Lundkvist, a professor at the university. SaNOtize the miraculous revolutionary nasal spray to eradicate COVID-19 is manufactured by a global company, a biotech firm based in Vancouver, Canada discovering that SaNOtize nasal spray is 99.9 percent effective in killing COVID-19.
Uppsala University, which first discovered the powerful efficacy of nitric oxide, is a Swedish research university in Uppsala, Sweden. It was founded in 1477, it is the oldest university in Sweden, and all of the Nordic countries still in operation, It has ranked among the world’s 100 best universities in several high-profile international rankings during recent years. The university uses “Gratiae veritas naturae” as its motto and embraces natural sciences.
Presently, SaNOtize nasal spray is still awaiting emergency approval, but looked upon as the greatest shield and weapon against COVID-19. Dr. Gilly Regev, the CEO and co-founder of SaNOtize Research and Development Corp says that nitric oxide-releasing nasal spray, the only proven therapy against COVID-19, is currently undergoing Phase 11 clinical trials in Canada.
The SaNOtize treatment kills the virus in the upper airways, preventing it from incubating and making its way down to the lungs. In the past, SaNOtize has exhibited its excellence in its NORSTM (Nitric Oxide Releasing Solution) formulation of eradicating different types of viruses such as influenza and H1N1. On working trials, it has powerful efficacy in preventing and treating COVID-19 infections.
On clinical trials, patients treated with SaNOtize’s spray saw an average viral log reduction of 1.362 in the first 24 hours, which corresponds to a decline of around 95%. Within 72 hours the viral load crashed by more than 99%. The self-administered nitric oxide spray, developed by SaNOtize, is said to have yielded promising results in its UK and Canada clinical trials, including against the UK variant.
On records released by the researchers, a randomized, double-blind, placebo-controlled trial that evaluated 79 confirmed cases of COVID-19, with a 1:1 ration of placebo (saline) to NONS treatment. SaNOtize’s treatment for the prevention and early treatment of COVID-19 succeeded in reducing the log10 viral load in highly infected patients by 1.364, which corresponds to more than 95% in 24 hours, and by more than 99% within 72 hours. The majority of these patients had been infected with the UK variant.
Stephen Winchester, consultant medical virologist and chief investigator of the UK NHS clinical trial, said he expected the nasal spray “to be a major advance in the global battle against the devastating human impacts of the Covid-19 pandemic.”
An Israeli scientist who helped to develop the spray said that the anti-COVID nasal spray in approval queue could be game changer for India as it battles a massive second wave of the pandemic.
The CEO and co-founder of SaNOtize in Canada, Dr. Gilly Regev
Dr. Gilly Regev said, “The company is preparing submissions to worldwide regulators for emergency approval. “We are currently working to find the right partner in India and hoping it will be approved as a medical device in India to prevent Covid-19,” She also said, “What I would have loved right now is to go and give this to a whole town in India and show that everyone using it is not getting infected,”
She added, “We would have saved millions of lives if we could have brought it to market last year.”
She explained that getting regulatory approval and funds to commercially manufacture a new product took time. “In order to convince pharma companies and regulators it is effective, you need the data first,” she said. “It’s something you can carry with you like a hand sanitizer and use every time you might have been exposed,” she further explained, adding that countries could also use it to “fill the gap” whilst vaccinating their populations.
SaNOtize is planning to get 4,000-5,000 people to take part in the Phase III trials. “We are hoping part of our Phase III trials could be done in India. We are looking for the final funding for Phase III ,” she said. “We are also exploring manufacturing sites around the world.”
SaNOtize is also applying to regulatory authorities in the UK and Canada for emergency use authorization. Israel and New Zealand have given interim approval for the sale of biotech firm SaNOtize Research and Development’s Nitric Oxide Nasal Spray (NONS) which could help prevent transmission of the COVID-19 virus, news agency Reuters reported, citing the company. SaNOtize Research & Development Corp. is a biotech company based in Vancouver, Canada.
Dr. Gilly Regev, PhD and Dr. Chris Miller, PhD, BA, RT are co-founders of SaNOtize. Dr. Regev and Dr. Miller are among a small group of people who are experts at using nitric oxide therapeutically. The SaNOtize leadership team is complemented by a number of talented researchers, scientists and accomplished entrepreneurs, and is advised by a distinguished board of directors..
Meantime, Israel and New Zealand give interim approval for sale of SaNOtize nasal spray.
There is a lingering fear that forces with power and money might manipulate the pharma in order to promote certain brands and block the breakthrough nasal spray. There is another rising worry that perhaps nation leaders do want populous masses to die to clear up the population, thus would deliberately withhold such revolutionary treatments coming through.
On reiterating Dr. Gilly Regev words, she had very kindly and behovelently said said, “What I would have loved right now is to go and give this to a whole town in India and show that everyone using it is not getting infected.” This reveals her beautiful heart! Time will tell whether this nasal spray will be selling in India at affordable prices for the vast population.